MELBOURNE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Immuron ( (IMRN)) has provided an update.

March 2025 Quarter AUD$0.5 million up 28% on prior year March 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; ...

Strong continued growth of Travelan® sales reported in all markets North American Travelan® sales up by 98% YoY in the first half of FY20 Immuron achieved 55% YoY growth for the first half of FY20, ...

Immuron Limited, an Australian-based and globally integrated biopharmaceutical company, has announced the interim topline results confirming that a single daily dose of Travelan is effective in ...

Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...

MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued ...

Alaven Consumer Healthcare has launched Travelan (bovine colostrum [anti-enterotoxigenic Escherichia coli antibodies]) caplets to reduce the risk of traveler’s diarrhea (often referred to as ...